National Immunodeficiency Strategy | ASCIA TAPID Project | APID Training Meetings | ASCIA Immunodeficiency Register

ASCIA has significantly expanded its range of information for health professionals and patients on Primary Immunodeficiency (PID) since 2014, including the ASCIA Transplantation and PID (TAPID) Project, development of  resources to support the use of subcutaneous immunoglobulin (SCIg) and a dedicated webpage   

National Immunodeficiency Strategy 

Following the success of the National Allergy Strategy, ASCIA is hosting a meeting in early March 2019 to progress the development of the first National Immunodeficiency Strategy for Australia.

The National Immunodeficiency Strategy mission is to improve the health and quality of life for Australians with primary immunodeficiencies and minimise the burden on individuals, carers, healthcare services and community.

The March 2019 meeting will involve representatives from:

• ASCIA - Clinical Immunologists and Nurses
• Patient organisations - AusPIPS, IDFA, IDFNZ, HAE Australasia
• Relevant foundations (e.g. Jeffrey Modell)
• Regulatory bodies (e.g. National Blood Authority, Jurisdictional Blood Committee).
• Supply channels (e.g. Australian Red Cross Blood Service, Pharmacists)
• Allied health professions (e.g. Dietitians, Physiotherapists, Occupational Therapists)

The draft goals on the National Immunodeficiency Strategy are as follows:
1. Develop expert centres throughout Australia to provide early and appropriate diagnosis of primary immunodeficiencies, including newborn screening and genomic diagnosis.
2. Improve access to appropriate medical and nursing specialist care and training for patients (adults and children) with primary immunodeficiencies.
3. Recognise complexity of care required for primary immunodeficiencies in hospital care priorities, funding models, e-health and coding.
4. Improve access to comprehensive multidisciplinary care, including dietitians, physiotherapists and occupational therapists for patients (adults and children) with primary immunodeficiencies.
5. Ensure sufficient supply of Immunoglobulin Replacement Therapy (IRT) and Hereditary Angioedema (HAE) treatments for patients (adults and children) with primary immunodeficiencies.
6. Ensure appropriately supported and funded choices of IRT, including subcutaneous or intravenous immunoglobulin (SCIG or IVIG) and HAE treatments for patients (adults and children) with primary immunodeficiencies.


The ASCIA TAPID (Transplantation and PID) project is an important and ongoing collaboration between clinical immunologists, transplant physicians and international PID experts, facilitated by ASCIA. 

The next face to face TAPID meeting is scheduled for Saturday 25 May to Sunday 26 May 2019.

The main objective of the TAPID project is to have regular collaborations and discussions between immunologists and  transplant physicians in major centres that transplant patients with PIDs in Australasia.  TAPID meetings enable complex PID and transplantation cases to be discussed in a confidential expert forum.

At the ASCIA PID (APID) Consultants Meeting in May 2013 the concept of the TAPID (transplantation and PID) project was initiated. Since then:
  • TAPID face to face meetings have been held in February 2014, May 2017 and May 2018.
  • The TAPID project membership has increased from 12 to more than 90 members.
  • TAPID teleconferences are now held each month.  

The TAPID project has been supported by unrestricted educational grants from CSL Behring.

Current TAPID members

Prefix  First Name Surname
Dr Fuad Abbas
Mr Frank Alvaro
Dr Rani Bhatia
Dr Annaliesse Blincoe (NZ) 
Dr Julian Bosco
Dr Jack Bourke
Dr Tim Brettig
Dr Maia Brewerton
Dr Shannon Brothers (NZ)
Prof Dianne Campbell
Dr Tina Carter
Dr Damien Chan
Dr Kritika Chetty
Dr Abigail Cheung
Dr Sharon Choo
Dr Julia Clark
Dr Catherine Cole
Dr Theresa Cole 
Dr Rachel Conyers
Dr Graham Davies (UK)
Dr Theo De Malmanche
Prof Jo Douglass
Dr Luke Droney
Ms Rachael Dunn
Dr Jacqueline Fleming 
Dr Lara Ford
Dr Chris Fraser
Dr Katie Frith
Dr Melissa Gabriel
Dr Andy Gennery (UK)
Dr  David Gillis
Dr Nicole Gilroy
Dr Paul Gray
Dr Laine Hosking
Dr Kuang-Chih Hsiao
Dr Peter Hsu 
Dr Benedicta  Itotoh
Dr Henning Johannsen
A/Prof Alyson Kakakios
Dr  Alisa Kane
Dr Steven Keogh
Dr  Jovanka King
Dr  Shruti Kohli 
Dr Michael Lane
Dr Omega Leong
A/Prof Richard Loh
Dr Paxton Loke 
Prof Michaela Lucas
Dr Tracy Markus
Dr Kylie Mason
Dr Jeremy McComish
Dr Andrew McLean-Tooke
Dr Peter McNaughton
Dr Francoise Mechinaud
Dr Sam Mehr
Dr Richard Mitchell
Dr Saravanan Muthusamy
Dr Mahila Namasivayam
Dr Katherine Nicholls
Dr Tracey O'Brien
Dr Samar Ojaimi
Dr Michael O'Sullivan 
Dr Manika Pal
Dr Jane Peake
Dr  Linny Phuong
Dr Kahn Preece (NZ)
Dr Tim Prestidge (NZ)
Dr Patrick Quinn
Dr Shanti Ramachandran
Dr Christiane Remke
Dr Stephanie Richards
A/Prof Peter Richmond
Dr David Routledge
Dr Kristina Rueter
Dr Sabeena Selvarajah
Dr Bella Shadur 
Dr Peter Shaw 
Dr Jan Sinclair (NZ)
Dr Charlotte Slade
Dr Joanne Smart
Dr  Trisha SooshayRaj
Dr Shruti Swamy
Dr Heather Tapp
Dr  Grace Thompson
Dr Toby Trahair
Dr Gary Unglik
Mr Ben Van Dort
Dr Brynn Wainstein
Dr Melanie Wong
Prof John Ziegler

ASCIA PID (APID) Training Meetings

The next ASCIA Primary Immunodeficiency Training Meeting is scheduled for Sunday 26 May to Thursday 30 May 2019. 

For more details go to

ASCIA Immunodeficiency (ID) Register

This Register is currently in the final stage of development.

The objectives of this project are to:

  • Collect data on all patients with primary immune deficiency diseases in Australia and New Zealand.
  • Enhance research, therapies and advocacy for primary and secondary immune deficiencies.

This project has been supported by unrestricted educational grants from CSL Behring and Octapharma.

Content Updated January 2019

Mod ASCIA Member
Donate to AIFA
go to NAS website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.


This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information.Verify here.